Original from: Castle Biosciences
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed.
¡°This proposed transaction underscores our commitment to the gastrointestinal (GI) community-providers and patients,¡± said Derek Maetzold, president and chief executive officer of Castle Biosciences. ¡°Our growth initiatives include the continual assessment of complementary technologies. With Previse, we found an opportunity to expand our offerings within our GI vertical, beyond our spatialomics TissueCypher Barrett¡¯s Esophagus test, allowing us to offer customers a more robust set of testing options. Previse¡¯s methylation technology, as well as its pipeline technologies, provide us with the potential to address existing unmet needs, including potential upstream opportunities.¡±
¡°We are excited about joining Castle,¡± said Daniel Lunz, chief executive officer of Previse. ¡°We look forward to the advancements to care we can make together for patients with GI diseases-our technologies, combined with Castle¡¯s TissueCypher test and history of executional success.¡±
The transaction is expected to close in the coming weeks, subject to the customary closing conditions.
